View in EDS HTML Full Text PDF Full Text

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.

Saved in:
Bibliographic Details
Title: Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Authors: Klein-Brill A; Anthem Innovation Israel, Ltd, Tel Aviv, Israel., Amar-Farkash S; Anthem Innovation Israel, Ltd, Tel Aviv, Israel., Lawrence G; Anthem Innovation Israel, Ltd, Tel Aviv, Israel., Collisson EA; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco., Aran D; Anthem Innovation Israel, Ltd, Tel Aviv, Israel.; Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.; The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel.; Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Source: JAMA network open [JAMA Netw Open] 2022 Jun 01; Vol. 5 (6), pp. e2216199. Date of Electronic Publication: 2022 Jun 01.
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35675073
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Klein-Brill+A%22">Klein-Brill A</searchLink>; Anthem Innovation Israel, Ltd, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Amar-Farkash+S%22">Amar-Farkash S</searchLink>; Anthem Innovation Israel, Ltd, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Lawrence+G%22">Lawrence G</searchLink>; Anthem Innovation Israel, Ltd, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Collisson+EA%22">Collisson EA</searchLink>; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.<br /><searchLink fieldCode="AU" term="%22Aran+D%22">Aran D</searchLink>; Anthem Innovation Israel, Ltd, Tel Aviv, Israel.; Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.; The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel.; Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101729235%22">JAMA network open</searchLink> [JAMA Netw Open] 2022 Jun 01; Vol. 5 (6), pp. e2216199. <i>Date of Electronic Publication: </i>2022 Jun 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101729235 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2574-3805 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225743805%22">25743805 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Netw Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35675073
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jamanetworkopen.2022.16199
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e2216199
    Titles:
      – TitleFull: Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Klein-Brill A
      – PersonEntity:
          Name:
            NameFull: Amar-Farkash S
      – PersonEntity:
          Name:
            NameFull: Lawrence G
      – PersonEntity:
          Name:
            NameFull: Collisson EA
      – PersonEntity:
          Name:
            NameFull: Aran D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2022 Jun 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2574-3805
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: JAMA network open
              Type: main
ResultId 1